The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1 trial of gavocabtagene autoleucel (gavo-cel, TC-210) in patients (pts) with treatment refractory mesothelioma and other mesothelin-expressing solid tumors.
 
Raffit Hassan
Research Funding - Bayer (Inst); TCR2 Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Mesothelin domain-specific monoclonal antibodies and use thereof (Patent number:9803022) (Inst)
 
Marcus O. Butler
Honoraria - Bristol-Myers Squibb; Merck; Novartis; Roche
Consulting or Advisory Role - Adaptimmune; Adaptimmune; Bristol-Myers Squibb; EMD Serono; Genzyme; GlaxoSmithKline; GlaxoSmithKline; IDEAYA Biosciences; Immunocore; Immunovaccine; Instil Bio; Iovance Biotherapeutics; LaRoche Posay; Medison; Merck; Novartis; Pfizer; Regeneron; Sanofi; Sun Pharma
Research Funding - Merck (Inst); Novartis Canada Pharmaceuticals Inc (Inst); Takara Bio (Inst)
Expert Testimony - Merck
 
David Yoonsuk Oh
Consulting or Advisory Role - Maze Therapeutics
Research Funding - Merck (Inst); Nutcracker Therapeutics, Inc. (Inst); PACT Pharma (Inst); Parker Institute for Cancer Immunotherapy (Inst); Poseida Therapeutics (Inst); Roche/Genentech (Inst); TCR2 Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Inventor on patent claiming methods for the use and optimization of cytotoxic CD4+ T cell therapy for cancer.; Inventor on patent claiming methods to identify patients who will respond to or experience toxicity with cancer immunotherapies based on T cell receptor sequencing.
Travel, Accommodations, Expenses - Roche/Genentech
 
Roisin Eilish O'Cearbhaill
Honoraria - Curio Science; GlaxoSmithKline; MJH Life Sciences; MJH/PER
Consulting or Advisory Role - Aptitude Health; Bayer; Carina Biotech; Fresenius Kabi; GlaxoSmithKline; GOG Foundation; Immunogen; R-Pharm; Regeneron; Seagan
Research Funding - Acrivon Therapeutics (Inst); AstraZeneca/Merck (Inst); Atara Biotherapeutics (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Genmab (Inst); GlaxoSmithKline (Inst); GOG Foundation (Inst); Juno Therapeutics (Inst); Kite/Gilead (Inst); Ludwig Institute for Cancer Research (Inst); Merck/Genentech (Inst); Regeneron (Inst); Sellas Life Sciences (Inst); Syndax (Inst); TapImmune Inc. (Inst); TCR2 Therapeutics (Inst)
Travel, Accommodations, Expenses - Gathering Around Cancer; Hitech Health; Society of Gynecologic Oncology
Other Relationship - JAMA Oncology
(OPTIONAL) Uncompensated Relationships - Children's Medical Research Foundation (CMRF)
 
Lauren MacMullen
Employment - TCR2 Therapeutics
 
Erin Jeter
Employment - TCR2 Therapeutics
Stock and Other Ownership Interests - TCR2 Therapeutics
 
Udayan Guha
Employment - TCR2 Therapeutics
Stock and Other Ownership Interests - TCR2 Therapeutics
 
Viera P. Muzithras
Employment - TCR2 Therapeutics
 
Kevin Zikaras
Employment - TCR2 Therapeutics
 
Melissa Lynne Johnson
Consulting or Advisory Role - Abbvie (Inst); Amgen (Inst); ArriVent Biopharma (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Axelia Oncology (Inst); Black Diamond Therapeutics (Inst); Calithera Biosciences (Inst); Checkpoint Therapeutics (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); EcoR1 Capital (Inst); Editas Medicine (Inst); Eisai (Inst); Genentech/Roche (Inst); Genmab (Inst); Genocea Biosciences (Inst); GlaxoSmithKline (Inst); Gritstone Bio (Inst); IDEAYA Biosciences (Inst); ITeos Therapeutics (Inst); Janssen Oncology (Inst); Lilly (Inst); Merck (Inst); Mirati Therapeutics (Inst); Molecular Axiom (Inst); Novartis (Inst); Oncorus (Inst); Pyramid Biosciences (Inst); Regeneron (Inst); Revolution Medicines (Inst); Ribon Therapeutics (Inst); Sanofi (Inst); SeaGen (Inst); Takeda (Inst); Turning Point Therapeutics (Inst); VBL Therapeutics (Inst)
Research Funding - Abbvie (Inst); Acerta Pharma (Inst); Adaptimmune (Inst); Amgen (Inst); Apexigen (Inst); Arcus Biosciences (Inst); Array BioPharma (Inst); Artios (Inst); AstraZeneca (Inst); Atreca (Inst); BeiGene (Inst); BerGenBio (Inst); BioAtla (Inst); Black Diamond Therapeutics (Inst); Boehringer Ingelheim (Inst); Calithera Biosciences (Inst); Carisma Therapeutics (Inst); Corvus Pharmaceuticals (Inst); Curis (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Dracen (Inst); Dynavax Technologies (Inst); Elicio Therapeutics (Inst); EMD Serono (Inst); EQRx (Inst); Erasca, Inc (Inst); Exelixis (Inst); Fate Therapeutics (Inst); Genentech/Roche (Inst); Genmab (Inst); Genocea Biosciences (Inst); GlaxoSmithKline (Inst); Gritstone Bio (Inst); Guardant Health (Inst); Harpoon (Inst); Helsinn Healthcare (Inst); Hengrui Pharmaceutical (Inst); Hutchison MediPharma (Inst); IDEAYA Biosciences (Inst); IGM Biosciences (Inst); Immunitas (Inst); Immunocore (Inst); Incyte (Inst); Janssen (Inst); Kadmon (Inst); Kartos Therapeutics (Inst); Lilly (Inst); Loxo (Inst); Lycera (Inst); Memorial Sloan-Kettering Cancer Center (Inst); Merck (Inst); Merus (Inst); Mirati Therapeutics (Inst); NeoImmuneTech (Inst); Neovia Oncology (Inst); Novartis (Inst); Numab (Inst); Nuvalent, Inc. (Inst); OncoMed (Inst); Palleon Pharmaceuticals (Inst); Pfizer (Inst); PMV Pharma (Inst); Rain Therapeutics (Inst); Regeneron (Inst); Relay Therapeutics (Inst); Revolution Medicines (Inst); Ribon Therapeutics (Inst); Rubius Therapeutics (Inst); Sanofi (Inst); Seven and Eight Biopharmaceuticals (Inst); Shattuck Labs (Inst); Silicon Therapeutics (Inst); Stem CentRx (Inst); Syndax (Inst); Takeda (Inst); Tarveda Therapeutics (Inst); TCR2 Therapeutics (Inst); Tempest Therapeutics (Inst); Tizona Therapeutics, Inc. (Inst); Tmunity Therapeutics, Inc. (Inst); Turning Point Therapeutics (Inst); University of Michigan (Inst); Vyriad (Inst); Y-mAbs Therapeutics (Inst)
Travel, Accommodations, Expenses - Abbvie; AstraZeneca; Genentech; Incyte; Merck; Pfizer; Sanofi
 
Janos Laszlo Tanyi
No Relationships to Disclose
 
Azam Ghafoor
No Relationships to Disclose
 
Robert Tighe
Employment - TCR2 Therapeutics
Stock and Other Ownership Interests - TCR2 Therapeutics
 
Munisha Smalley
Employment - TCR2 Therapeutics
Stock and Other Ownership Interests - TCR2 Therapeutics
 
Alfonso Quintas-Cardama
Employment - TCR2 Therapeutics
 
David S. Hong
Stock and Other Ownership Interests - MolecularMatch; OncoResponse; Telperian
Consulting or Advisory Role - Acuta; Adaptimmune; Alkermes; Alphasights; Amgen; AUM Biosciences; Axiom Biotechnologies; Baxter; Bayer; Boxer Capital; Bridgebio; COG; Cor2Ed; Cowen; EcoR1 Capital; Genentech; Gennao Bio; Gerson Lehrman Group; Gilead Sciences; GroupH; Guidepoint Global; HCW Precision; Immunogen; Infinity Pharmaceuticals; Janssen; Liberum; MedaCorp; Medscape; Numab; Oncologia Brasil; Pfizer; Pharma Intelligence; Precision Oncology Experimental Therapeutics; Prime Oncology; RAIN; ST Cube; Takeda; Tavistock Life Sciences; Trieza Therapeutics; Turning Point Therapeutics; WebMD; YingLing Pharma; ZIOPHARM Oncology
Research Funding - Abbvie (Inst); Adaptimmune (Inst); Adlai Nortye (Inst); Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol Myers Squibb (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Eisai (Inst); Endeavor BioMedicines (Inst); Erasca, Inc (Inst); F. Hoffmann LaRoche (Inst); Fate Therapeutics (Inst); Genentech (Inst); Genmab (Inst); Ignyta (Inst); Infinity Pharmaceuticals (Inst); Kite, a Gilead company (Inst); Kyowa (Inst); Lilly (Inst); Loxo (Inst); MedImmune (Inst); Merck (Inst); Mirati Therapeutics (Inst); Mologen (Inst); National Cancer Institute (Inst); Navire (Inst); Novartis (Inst); Numab (Inst); Pfizer (Inst); Pyramid Biosciences (Inst); Seagen (Inst); Takeda (Inst); TCR2 Therapeutics (Inst); Teckro (Inst); Turning Point Therapeutics (Inst); VM Pharma (Inst)
Travel, Accommodations, Expenses - AACR; ASCO; Bayer Schering Pharma; Genmab; Society for Immunotherapy of Cancer; Telperian